Market Exclusive

Analyst Activity – Royal Bank Of Canada Raises Its Price Target On Sarepta Therapeutics (NASDAQ:SRPT) to $64.00

Analyst Ratings For Sarepta Therapeutics (NASDAQ:SRPT)

Today, Royal Bank Of Canada raised its price target on Sarepta Therapeutics (NASDAQ:SRPT) to $64.00 per share.

There are 3 hold ratings, 16 buy ratings, 1 strong buy rating on the stock.

The current consensus rating on Sarepta Therapeutics (NASDAQ:SRPT) is Buy (Score: 2.90) with a consensus target price of $61.90 per share, a potential 81.63% upside.

Some recent analyst ratings include

Recent Insider Trading Activity For Sarepta Therapeutics (NASDAQ:SRPT)
Sarepta Therapeutics (NASDAQ:SRPT) has insider ownership of 9.60% and institutional ownership of 73.13%.

Recent Trading Activity for Sarepta Therapeutics (NASDAQ:SRPT)
Shares of Sarepta Therapeutics closed the previous trading session at 34.08 up +0.19 0.56% with 4,122,871 shares trading hands.

Exit mobile version